As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

COYA 303 is an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 ... COYA 303 exhibited a dual immunomodulatory mechanism of action resulting in an additive ...

Get Instant Summarized Text (Gist) Glucagon-like peptide 1 receptor agonists (GLP1RA), used for type 2 diabetes and obesity, are linked to behavioral side effects. An analysis of genetic variants ...

As a result, semaglutide and its fellow glucagon-like peptide-1 drugs ... that we see are predictable when you understand the mechanism of action of these drugs,” Coviello told Salon.

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...